Hormone-Refractory Prostate Cancer
or Castrate-Resistant Prostate Cancer
Treating Maintaining Quality of Life
Treatments for Hormone Refractory Prostate Cancer
Second-Line Hormonal Therapies
There are three general categories of treatments for men with hormone refractory prostate cancer. The 2nd line hormonal therapies list includes drugs not usually listed as being a 2nd line treatment, but nevertheless they can play a role in either slowing down HRPC progression or lessening the tumor burden.
Second-line hormonal therapies. A list of what can be found on the 2nd-Line Hormonal Therapy web page is below. These are all documented with data from clinical trials, although in many cases the number of patients is small. Go to the 2nd-line hormonal therapy page for ketoconazole, DES and TDE and to the Proven-Other page for the remainder, noting that the "Other" category simply means that they are less proven than the standard 2nd line therapies -- they might lengthen the PSA doubling time, some might have PSA declines of less than 50% or provide a stable disease state. Here's the complete list:
Leukine and leukine combinations (leukine = gm-csf). Very expensive
Sandostatin LAR. Very expensive.
Avodart plus ketoconazole
Nilutamide (an alternative antiandrogen).
Revlimid and Ketoconazole or leukine and revlimid (Revlimid is very expensive).
Sunitinib (Sutent). Very expensive
Degarelix (Firmagon). A GnRH antagonist that might be better than e.g. Lupron
Chemotherapy. This is an extensive set of papers and tables covering use of chemotherapy with HRPC. The main focus has been on identifying chemotherapy that is effective as a 2nd line or greater chemotherapy since taxotere is an approved drug as a 1st line chemotherapy.
Radiation. Covered here are spot radiation, radiopharmaceuticals and more.
immunotherapy consisting of
autologous peripheral blood mononuclear cells (PBMC's), obtained
by leukapheresis and cultured (activated) with a recombinant
human protein (PAP-GM-CSF) consisting of prostatic acid
phosphatase linked to granulocyte-macrophage colony-stimulating
See www.provenge.com for more
information as well as full prescribing information.
See www.provenge.com for more information as well as full prescribing information.
Author: Howard Hansen 11/30/2008; updated 28 July 2010
This information related to HRPCa, AIPC, and/or CRPC is provided for educational purposes only and does not replace or amend professional medical advice. Unless otherwise stated and credited, the content of this website is by and the opinion of and copyright © 2001-2013 Howard Hansen and/or HRPCa Association, Inc. All Rights Reserved. Our policy regarding privacy, right to reprint and contact information are at About Us. We are a 501(c)(3) not-for-profit public charity.